ABSTRACT
A 47-year-old woman with nephrotic syndrome (membranous glomerulonephropathy) who excreted high, low density lipoproteins (HDL, LDL) which are almost similar to serum HDL and LDL, and small amount of slightly deformed very low density lipoprotein (VLDL) in the urine has been presented.
Subject(s)
Lipoproteins/urine , Nephrotic Syndrome/urine , Electrophoresis, Agar Gel , Electrophoresis, Polyacrylamide Gel , Female , Humans , Lipoproteins/blood , Lipoproteins, HDL/blood , Lipoproteins, HDL/urine , Lipoproteins, LDL/blood , Lipoproteins, LDL/urine , Lipoproteins, VLDL/blood , Lipoproteins, VLDL/urine , Middle Aged , Nephrotic Syndrome/bloodABSTRACT
Latamoxef (LMOX) is a new antibiotic synthesized by Shionogi Research Laboratory. Chemically LMOX is especially unique with a sulfur atom replacing the oxygen atom in the 1 position of the conventional cephalosporin nucleus, and in addition, this antibiotic has a cephamycin-like structure. The antibacterial activity of LMOX shows high potency against Gram-negative bacteria, but tends to be weak against Gram-positive bacteria. The tissue levels of LMOX in humans after intravenous injection of 1 g were examined. The levels in uterine and adnexa uteri tissue at 1 hour after administration were 25.4 and 27.4 micrograms/g respectively. LMOX was administered to 147 cases in infections of obstetric and gynecological field. The clinical effect according to disease was 94.6% for intrauterine infections, 95.0% for adnexitis, 87.0% intrapelvic infections, and 100% for external genital organ infections, making a total of 92.5%. The rate of occurrence of side effects or abnormal laboratory findings was similar to or slightly less than that seen with other beta-lactam antibiotics.
